CAR T-cell Therapy Articles | Page 2

Considerations for CAR T-Cell Therapy in NHL
Babis Andreadis, MD, discusses the successes seen with CAR T-cell development in the past year and the use of CAR T-cell therapy in patients with NHL.
Beyond CARs: New T-Cell Strategies Take Center Stage
Recent advances in the understanding of the immune system are paving the way for new and effective approaches to treating cancer.
The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant. 
Axi-Cel Plus Atezolizumab Active, Safe in DLBCL
The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.
Prime Time for CAR T Cells
Chimeric antigen receptor (CAR) T cells have hit prime time, with the 2 recent FDA approvals for this class of cell-based therapy.
Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tisagenlecleucel Continues to Impress in DLBCL
The CAR T-cell therapy tisagenlecleucel (Kymriah) achieved an overall response rate of 53.1% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.
BCMA-Directed bb2121 Highly Effective for Myeloma
Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma. 
Expert Highlights Advances in CAR T-Cell Therapy
Noelle Frey, MD, discusses the FDA approvals of CAR T-cell therapies, as well as the bright future of the treatment.
FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
The FDA has granted the the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma.
Publication Bottom Border
Border Publication